Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA
Sarah C. Rutherford(NewYork–Presbyterian Hospital), Peter Martin(Northwestern University), Gila Sellam(Roche (Switzerland)), Laurie H. Sehn(BC Cancer Agency), Maurizio Martelli(University of Milan), Michael Herold(Friedrich Schiller University Jena), Judith Trotman(The University of Sydney), Marek Trněný(Charles University), Deniz Şahin(Roche (Switzerland)), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Robert Marcus(King's College Hospital), Tina Nielsen(Roche (Switzerland)), Umberto Vitolo(Candiolo Cancer Institute), Federico Mattiello(Roche (Switzerland)), Lale Kostakoglu(Mount Sinai Hospital)
Cited by 23
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k